Skip to main content

Table 1 Patient timeline clinical history

From: Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Days from HSCT

Clinical condition/therapeutic intervention

0

HSCT

17

Neutrophil recovery

19

Platelet recovery

22

aGvHD onset: diarrhea (st.I) and skin (st.II). Started PDN-equivalent 2 mg/kg/iv

28

Diarrhea exceeded 1500 mL/day (st.III) and started budesonide 3 mg tid po

29

Diarrhea exceeded 2000 mL/day (st.IV) and started MMF 1 g tid iv

33

EGDS with biopsies (GvHD confirmation). Started Ruxolitinib 5 mg bid

36

Steroid taper

39

Diarrhea below 1000 mL and Ruxolitinib 5 + 10 mg/day. Stop MMF

45

Resumed oral food intake

49

Switch to oral CsA

54

EGDS with biopsies: no signs of GvHD

61

Switch PDN po

66

Reduced Ruxolitinib to 5 mg bid

70

Patient discharged

100

Reduced Ruxolitinib to 5 mg/day

135

Steroid stopped

156

Ruxolitinib stopped

  1. abbreviations: HSCT hematopoietic stem cell transplantation, aGvHD acute graft-vs.-host disease, PDN prednisone, iv intravenously, po orally, MMF mycophenolic acid, EGDS esophagous-gastro-duodenoscopy, CsA cyclosporine A, bid twice daily, tid three times a day, st stage